🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

ViiV Healthcare clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and Ireland registers with ViiV Healthcare as lead sponsor. Synced 26 Sep 2026
19Current trials
7Recruiting now
16Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

ViiV Healthcare is the lead sponsor of 19 current clinical trials in our USA, UK and Ireland registers. 7 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Cabotegravir, Cab La and RHuPH20. The most-studied condition is HIV Infections.

Company profile on this site (news, sites, medicines, approvals): GSK (GB) →

ClinicalTrials.gov trials by status

  • Recruiting737%
  • Active, closed1263%

Trials by phase

  • Phase 1842%
  • Phase 3737%
  • Phase 2316%
  • Phase 1/215%
01

Clinical trials sponsored by ViiV Healthcare

19 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
NCT06724640 · HIV Infections
Phase 1 Recruiting 2024-12 USA
First Time in Human Study of Long Acting VH4524184 Formulations
NCT06310551 · HIV Infections
Phase 1 Recruiting 2024-03 USA
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546 · ClinicalTrials.gov ↗ · HIV Infections
Phase 2 Recruiting 2026-02 USA
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916 · ClinicalTrials.gov ↗ · HIV Infections
Phase 3 Recruiting 2026-06 UK, USA
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
NCT05418868 · ClinicalTrials.gov ↗ · HIV Infections
Phase 1 Recruiting 2022-06 USA
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
NCT05674656 · ClinicalTrials.gov ↗ · HIV Infections
Phase 1/2 Recruiting 2023-07 USA
A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
NCT07525544 · ClinicalTrials.gov ↗ · HIV Infections
Drug: Midazolam
Phase 1 Recruiting 2026-05 USA
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT05996471 · HIV Infections
Phase 2 Active, closed 2023-08 USA
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311 · HIV, HIV Infections
Phase 3 Active, closed 2024-02 Ireland, UK
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520 · HIV Infections
Phase 3 Active, closed 2016-10 UK, USA
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503 · ClinicalTrials.gov ↗ · HIV Infections
Phase 3 Active, closed 2015-02 Ireland, UK, USA
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384 · ClinicalTrials.gov ↗ · HIV Infections
Drug: VH3810109
Phase 1 Active, closed 2025-07 UK, USA
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049 · ClinicalTrials.gov ↗ · HIV Infections
Phase 3 Active, closed 2017-10 USA
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052 · ClinicalTrials.gov ↗ · Infection, Human Immunodeficiency Virus, HIV Infections
Phase 3 Active, closed 2016-10 USA
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT06741397 · ClinicalTrials.gov ↗ · HIV Infections
Drug: Cab La
Phase 2 Active, closed 2024-12 USA
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
NCT06652958 · ClinicalTrials.gov ↗ · HIV Infections
Phase 1 Active, closed 2024-10 USA
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV
NCT06970223 · ClinicalTrials.gov ↗ · HIV Infections
Phase 1 Active, closed 2025-04 USA
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805 · ClinicalTrials.gov ↗ · HIV Infections
Drugs: Cab La, Rpv La
Phase 3 Active, closed 2024-12 USA
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
NCT06786520 · ClinicalTrials.gov ↗ · HIV Infections
Drugs: Cab La, Cab Ula
Phase 1 Active, closed 2025-01 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in ViiV Healthcare trials

16 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in ViiV Healthcare trials

3 conditions
HIV Infections19HIV1Infection, Human Immunodeficiency Virus1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA187
Clinical trials in UK51
Clinical trials in Ireland20

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in HIV Infections

SponsorTrials
CellSight Technologies1

Sponsors with the most current trials registered for this condition.

06

Questions about ViiV Healthcare trials

How many clinical trials does ViiV Healthcare sponsor?

ViiV Healthcare is the lead sponsor of 19 current trials on ClinicalTrials.gov in our USA, UK and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are ViiV Healthcare trials recruiting?

Yes. 7 of its 19 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is ViiV Healthcare testing?

Its current trials name 16 drugs and biologicals as interventions. The most frequent are Cabotegravir (5), Cab La (4), RHuPH20 (3), Rilpivirine (3) and Cab Ula (2). The number in brackets is how many of its trials name each drug.

Does ViiV Healthcare have clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.